WELCOME TO The Biotechnology REPORT
Internal Systems Limited (ISL)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
PR Newswire | September 07, 2020
Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...
BioSpace | March 02, 2020
Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company has rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance its lead therapeutic candidates into clinical studies. The financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase I clin...
Cell and Gene Therapy
Innovent Biologics | February 21, 2022
Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...
IONpath, Inc. | August 27, 2021
Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology. Through this new program, customers can benefit from in-depth immune profiling and spatial analysis performed with the company's 30-marker Checkpoint Panel on its MIBIscope™ System.
Industrial Impact, Medical
AI, Industrial Impact
Industrial Impact, Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE